HW071021

HW071021 is a small molecule inhibitor targeting Son of sevenless homolog 1 (SOS1), a guanine nucleotide exchange factor involved in the activation of RAS proteins. By inhibiting SOS1, HW071021 aims to disrupt the RAS signaling pathway, which is frequently dysregulated in various cancers, particularly those with KRAS mutations. The drug is being developed primarily for the treatment of advanced malignant solid neoplasms and KRAS mutation-related tumors. It is currently in Phase 1 clinical trials for advanced solid tumors and has been developed by Wuhan Humanwell Innovative Drug R & D Center Co., Ltd., with involvement from KinoTeck Therapeutics and Humanwell Healthcare[1][2][3][5].